Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120610 | 1.00 | F10 (0.51) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6530276 | 0.92 | F10 (0.50) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6530273 | 0.92 | F10 (0.50) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5511337 | 0.91 | F10 (0.54) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5511332 | 0.91 | F10 (0.54) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5107723 | 0.90 | MAOB (0.48) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5107726 | 0.90 | MAOB (0.48) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5122475 | 0.89 | MAOB (0.46) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5122473 | 0.89 | MAOB (0.46) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5110332 | 0.89 | MAOB (0.47) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | PFIZER INC | 2008-10-23 | — | — | US | disclosed |
| EP-1869029-A1 | AN OXINDOLE OXAZOLIDINONE AS ANTIBACTERIAL AGENT | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106426-A1 | AN OXINDOLE OXAZOLIDINONE AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | F10 1720/4885MAOB 1778/4885MAOA 1789/4885 |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | OXA1L, OXSR1, OXER1 | F10 784/4885MAOB 412/4885MAOA 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.